ESR1 and breast carcinoma: In the present study, four different RSV analogs were developed and their effects on ERα/NGB pathway were compared with RSV-conjugated gold nanospheres as a prodrug to evaluate if RSV derivatives maintain breast cancer cell susceptibility to the chemotherapeutic drug paclitaxel as the non-conjugated compound.